230例药物性肝损伤患者临床特征分析*

doi:10.3969/j.issn.1672-5069.2024.06.018

摘要/Abstract

摘要： 目的总结分析230例药物性肝损伤(DILI)患者的临床特征。方法 2020年3月～2023年3月我院诊治的DILI患者230例,常规行血生化检查,采用免疫印迹法检测血清抗核抗体(ANA),采用免疫散射比浊法检测血清免疫球蛋白 (Ig)G和IgM。结果在230例DILI患者中,肥胖占45.7%,2型糖尿病占37.8%,高脂血症占43.5%; 基础疾病中感染性疾病占23.5%,心血管疾病占17.0%,肿瘤占13.0%;肝细胞损伤型占61.7%,胆汁淤积型占24.4%,混合型占13.9%;单一用药者占58.3%,双联用药者占22.6%,三联用药者占13.0%,四联用药及以上者占6.1%;＜3级(轻中度)肝损害占58.7%,≥3级(重度)肝损害占41.3%;血清IgM水平为(1.2±0.1) mg/ml,IgG水平为(10.6±2.1) g/L,血清抗核抗体阳性占27.5%;经降酶退黄治疗,本组患者痊愈,无死亡病例。结论本组DILI患者较年轻,可能与不适当用药有关。经停药和护肝治疗,大多预后良好。

关键词: 药物性肝损伤, 临床特征, 预后

Abstract: Objective The aim of this study was to summarize clinical feature of patients with drug-induced liver injury (DILI) in order to improve clinical management. Methods 230 patients with DILI were encountered in our hospital between March 2020 and March 2023, and the demographic data, clinical manifestations, and clinical tests were retrospectively reviewed and summarized. Serum antinuclear antibody (ANA) was assayed by Western blot, and serum IgG and IgM were detected routinely. Results Of 230 patients with DILI, obesity accounted for 45.7%, diabetes type 2 for 37.8% and hyperlipidemia for 43.5%; as for underlying diseases, infection accounted for 23.5%, cardiovascular diseases for 17.0% and tumor for 13.0%; patients with hepatocellular injury accounted for 61.7%, cholestatic injury for 24.4% and mixed type for 13.9%; one single alleged medicines accounted for 58.3%, double for 22.6%, trible for 13.0% and quadruplex for 6.1%; mild to moderate liver injury accounted for 58.7% and severe for 41.3%; serum IgM and IgG levels were normal, and serum ANA positive for 27.5%; all patients in our series recovered without death. Conclusion Patients with DILI in our series is relatively young, inappropriate medication might be involved in pathogenesis and the prognosis is good.

Key words: Drug-induced liver injury, Clinical feature, Prognosis

李靖, 何海滨, 李春婷, 石磊. 230例药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 870-873.

Li Jing, He Haibin, Li Chunting, et al. Clinical features of patients with drug-induced liver injury: Analysis of 230 cases[J]. Journal of Practical Hepatology, 2024, 27(6): 870-873.

参考文献

[1] Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers, 2019, 5(1):58.
[2] Björnsson HK, Björnsson ES. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med, 2022, 97:26-31.
[3] Garcia-Cortes M, Robles-Diaz M, Stephens C, et al. Drug induced liver injury: an update. Arch Toxicol, 2020, 94(10):3381-3407.
[4] Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int, 2019, 39(1):31-41.
[5] Chalasani NP, Maddur H, Russo MW, et al. ACG Clinical Guideline: Diagnosis andmanagement of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2021, 116(5):878-898.
[6] 陈高峰, 平键, 顾宏图, 等. 慢性乙型肝炎患者FibroTouch和FibroScan检测肝脏硬度与肝组织学Ishak纤维化评分的相关性分析. 中华肝脏病杂志, 2017, 25(2):145-150.
[7] Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54(3):931-939.
[8] Zhang J, Zhu X, Li Y, et al. Correlation of CpG islandmethylation of the cytochrome P450 2E1/2D6 genes with liver injury induced by anti-tuberculosis drugs: A nested case-control study. Int J Environ Res Public Health, 2016, 13(8):E776.
[9] 刘靓懿,宿冬远. 药物性肝损伤与自身免疫性肝炎临床和肝组织病理学特征比较研究. 实用肝脏病杂志,2018,21(3):463-464.
[10] Wang X, Song A, Lin X, et al. Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases. Front Immunol, 2022, 13: 1031291.
[11] 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志, 2023, 31(4):355-384.
[12] Eraslan C, Kiseo lu Ö F K, Meydan N, et al. Comparison of the results of ultrasonography-guided percutaneous liver mass biopsy performed with 18 and 20 gauge needles. Ege Tip Dergisi, 2019, 58(1): 8-12.
[13] 杨雪, 涂荣芳, 杨晋辉. 498例药物性肝损伤患者的临床特点及其预后分析. 中华肝脏病杂志, 2022, 30(7):735-740.
[14] 汪佩文, 董育玮, 李郑红, 等. 94例不明原因肝功能异常患者临床与肝组织病理学分析. 实用肝脏病杂志, 2018, 21(2):225-228.
[15] Yang LX, Liu CY, Zhang LL,et al. Clinical characteristics of patients with drug-induced liver injury. Chin Med J (Engl), 2017, 130(2):160-164.
[16] Shen T, Liu Y, Shang J, et al. Incidence andetiology of drug-induced liver injury in mainland China. Gastroenterology, 2019, 156(8):2230-2241.
[17] Cordina M, Hameen-Anttila K, Lauri J, et al. Health and medication literacy and the desire to participate in pharmacotherapy decision making-comparison of two countries. Res Social Adm Pharm, 2018, 14(9):817-823.
[18] 赖荣陶, 王晖, 桂红莲, 等. 138例药物性肝损伤患者的临床特征及肝脏组织学改变. 中华肝脏病杂志, 2012, 20(3):185-189.
[19] Devarbhavi H, Raj S. Drug-induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. Liver Int, 2019, 39(5):802-811.
[20] Low EXS, Zheng Q, Chan E, et al. Drug induced liver injury: East versuswest-a systematic review and meta-analysis. Clin Mol Hepatol, 2020, 26(2):142-154.
[21] Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 2008, 135(6): 1924-1934,e4.
[22] De Baetselier E, Dilles T, Batalha LM, et al. Perspectives of nurses' role in interprofessional pharmaceutical care across 14 European countries: a qualitative study in pharmacists, physicians and nurses. PLoS One, 2021, 16(5):e0251982.
[23] Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int, 2022, 42(9):1999-2014.

230例药物性肝损伤患者临床特征分析^*

Clinical features of patients with drug-induced liver injury: Analysis of 230 cases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐曼曼, 杨颜榕, 李珊珊, 武羽, 杨雪, 段钟平, 陈煜. 我院近10年肝衰竭患者预后变化趋势分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 874-877.
[2]	丘仲琼, 林建辉, 翁钘钘, 陈丽霞, 刘海钰. 影响慢加急性乙型肝炎肝衰竭并发医院获得性肺炎患者预后危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 878-881.
[3]	董旭, 秦阳华, 廖威, 许明晓, 葛玲玲, 李成忠. 乙型肝炎肝硬化和慢加急性肝衰竭患者并发感染影响因素与预后分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 891-894.
[4]	伊芬秀, 伊芬锦, 娄仲雷. 2型糖尿病合并细菌性肝脓肿患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 935-938.
[5]	周云松, 赵琦, 胡芳, 李叙颖, 崔峻松, 黄敬, 黄娜娜, 赵一鹏. 葛根素通过抑制AHR/氧化应激途径改善酮康唑诱导的大鼠肝损伤研究[J]. 实用肝脏病杂志, 2024, 27(5): 669-672.
[6]	王燕燕, 周桐桐, 卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 721-724.
[7]	王娟, 郑自通, 刘丽华, 何鑫, 姚旭, 彭灿. 接受雷公藤制剂治疗的类风湿性关节炎并发药物性肝损害患者临床特征及预后分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 733-736.
[8]	张怀东, 雷宇, 周智. 失代偿期肝硬化合并肝外脓肿患者临床特点分析[J]. 实用肝脏病杂志, 2024, 27(5): 761-764.
[9]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[10]	张丽, 陈雅雯, 盖琳, 邱红, 甄鑫, 常静霞. 乙型肝炎病毒/丙型肝炎病毒共同感染患者临床特征及其对抗病毒治疗应答反应研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 523-526.
[11]	潘劲劲, 谢琴秀, 许夕海, 郜玉峰, 李家斌. 药物性肝损伤患者血清抗核抗体阳性临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 543-546.
[12]	李勇, 张蕾, 吴幸福. 老年药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 547-550.
[13]	黄静, 王菁, 方亮, 周娟, 商惠民. 血清wnt5a和LC3-Ⅱ联合MELD评分预测慢加急性乙型肝炎肝衰竭患者短期预后价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 551-554.
[14]	姜正伟, 周冰清, 汤洁, 蒋蓓莉. 血清抗糖蛋白210抗体阳性的原发性胆汁性胆管炎患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 378-381.
[15]	郎平, 崔闪闪, 赵艳. 药物性肝损伤患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 382-385.